Medicure ( TSXV: MPH:CA ) signed an asset purchase agreement with CanAm Bioresearch to acquire the patent and intellectual property related to the discovery of new chemical entities that can be developed for therapeutic use. These new chemical entities are not being applied in Medicure's ( MPH:CA ) current Phase 3 study evaluating the use of MC-1 for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase deficiency. Medicure ( MPH:CA ) shall pay to CanAm 10% of net proceeds received with respect to transactions relating to assets, any license for P5P Analogues up to a maximum value payable to CanAm of $20M and the sale of an USFDA priority review voucher obtained in connection with the development of P5P analogues.
More on Medicure Financial information for Medicure.